At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases. Today, our primary focus is on Duchenne muscular dystrophy, limb-girdle muscular dystrophies, Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome A, and Charcot-Marie-Tooth disease.
SareptAssist is our patient support program designed to provide you with information to help you navigate the process of starting and staying on therapy. This program is available to patients in the United States.
With our deep focus on supporting rare disease communities and commitment to patient centricity, Sarepta's Patient Affairs team is the bridge between our company and the patient and caregiver communities we serve. Our direct work with individuals living with rare disease supports the ethos of Sarepta by establishing a sense of urgency and drive towards action.
Serving the rare disease community goes beyond developing precision genetic medicines. Corporate Giving is a core part of Sarepta’s mission.
Route 79, The Duchenne Scholarship Program, was created to support the post-secondary educational goals of students living with Duchenne.